XIFAXAN® - Antibiotic to Treat Travelers' Diarrhea
XIFAXAN (rifaximin) is a nonsystemic (which means it does not get in the bloodstream) antibiotic that treats a condition called travelers' diarrhea. It
is estimated that travelers' diarrhea affects 50,000 people each day all over the world.1
XIFAXAN is scientifically proven to treat travelers' diarrhea caused by certain kinds of the bacteria Esherichia coli or as they're more commonly known,
E. coli. Cases of travelers' diarrhea caused by E. coli are common in Latin America, the Caribbean, and Africa. E. coli may be responsible for
more than 70% of travelers' diarrhea cases in Mexico.2
Because XIFAXAN does not enter the bloodstream, it goes directly to the gut (gastrointestinal [GI] system). Other antibiotics go from the GI system directly
into the bloodstream. Because XIFAXAN remains in the GI tract, it allows you to reserve antibiotics that enter the bloodstream for infections
that require them.
XIFAXAN was approved by the Food and Drug Administration in May 2004, but rifaximin (the active ingredient in XIFAXAN) has been studied and used to treat
travelers' diarrhea around the world for decades. It's approved for use in 27 countries and has been prescribed for 23 years.3
To learn more about XIFAXAN, travelers' diarrhea symptoms, and travel tips, browse the menu to the left or speak to your healthcare provider.
References
Please click a link below to be taken to that area
Xifaxan Physician Resource Center
US Pharmacists
Xifaxan® (rifaximin) Tablets are indicated for the treatment of patients (≥12 years of age) with travelers' diarrhea caused by non-invasive strains of
Escherichia coli. Xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. Xifaxan should be
discontinued if diarrhea symptoms get worse or persist more than 24-48 hours and alternative antibiotic therapy should be considered.
In clinical trials, Xifaxan was generally well tolerated. The most common side effects (vs. placebo) were flatulence 11.3% (vs. 19.7%), headache 9.7% (vs. 9.2%), abdominal pain 7.2% (vs. 10.1 %), rectal tenesmus 7.2%
(vs. 8.8%), defecation urgency 5.9% (vs. 9.2%) and nausea 5.3% (vs. 8.3%).
Consult with your physician to see if this product is right for you.
For complete Prescribing Information, please click here.
For product information, adverse event reports, and product complaint reports please call:
Salix Product Information Call Center
Phone: 1-800-508-0024
Fax: 1-510-595-8183
Email: